PDL BioPharma — Merger or Acquisition (July 2016)
10 slides from PDL BioPharma's merger presentation, Jul 6, 2016
Slide 1: Noden Transaction Conference Call
¢PDL BioPharma’ Noden Transaction Conference Call July 6, 2016
Slide 2: Forward Looking Statements
Forward Looking Statements <3 This presentation contains forward-looking statements, including PDL’s expectations with respect to its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. A
Slide 3: Noden Transaction
Noden Transaction <3 «PDL has consummated an equity investment in Noden Pharma DAC and an affiliate (Noden). ¢ Investment is part of an acquisition of specialty pharma products. ¢ Equity used for asset acquisition and working capital. ¢ PDL will ultimately have ~88% ownership of Noden. @Noden ¢ Form
Slide 4: Hypertension and Tekturna
Hypertension and Tekturna <3 © Hypertension * Chronic condition with serious long term cardiovascular and renal implications affecting about one-third of US adult population = 78 million people. * Hypertension risk factors include stroke, heart attack, congestive heart failure and renal disease. * T
Slide 5: Tekturna Intellectual Property
Tekturna Intellectual Property <3 ¢ Tekturna is protected by multiple patents covering, e.g., composition of matter, pharmaceutical formulation and methods of manufacture which are part of the acquisition. ¢ United States — Composition of matter protection to 2018 for Tekturna; listed in the Orange
Slide 6: Key Business Terms
Key Business Terms <3 Structure ¢ Acquisition of exclusive worldwide rights to manufacture, market and sell Tekturna, Tekturna HCT, Rasilez and Rasilez HCT and API and finished product inventory. ¢ Transition * Phase 1 — Novartis continues to distribute Tekturna on behalf of Noden and Noden to recei
Slide 7: Financial Terms
Financial Terms <3 © Total commitment of up to $334M. ¢ Payments upon closing * Closing payment of $110M to Novartis and $40M working capital to Noden. — Funded by a $75M initial equity contribution from PDL and up to a $75 million inter-company loan which is expected to be repaid to PDL when Noden
Slide 8: Short Term Timeline
Short Term Timeline <3 ¢ Execution of documents ° May 24, 2016. ¢ Public announcement by PDL of signing with summary of terms. ¢ Hart-Scott-Rodino Filing ¢ May 31, 2016. ¢ FTC clearance received on June 30, 2016. ¢@ Closing ¢ July 1, 2016. ¢ Public announcement of FTC clearance by PDL and Noden on J
Slide 9: PDL Strategy
PDL Strategy <3 ¢ Noden is first significant equity investment for PDL in an operating company. @ PDL will consolidate Noden financials. ¢« Expected to be immediately accretive to cash earnings. ¢ Noden is expected to have a lower tax rate than PDL. ¢ Goal of acquiring additional specialty pharma pr
Slide 10: Question and Answer Session
QUESTION AND ANSWER SESSION